Do you, or would you consider, using diabetes medications off-label, such as a type 2 drug if you have type 1 diabetes?
Yes, and I already do
Yes, I would consider it if my diabetes care team agreed
Yes, I would consider it even if my diabetes care team didn't agree
No, I would not
I don't know or other
Total votes: 22
Do you, or would you consider, using diabetes medications off-label, such as a type 2 drug if you have type 1 diabetes?Poll dates: December 24 - 31, 2014
Total Votes: 22
Since its discovery, the sole treatment for type 1 diabetes has been injected insulin. In recent years, two new therapies for type 2 diabetes have been adopted by a small but growing number of adults with type 1 diabetes that have proven to be very helpful in achieving glucose and HbA1c targets. These are:
- GLP-1 agonists, taken by injection, which help reduce the magnitude of post-prandial blood sugar spikes and help limit inappropriate glucagon release. These drugs also cause feelings of fullness and have been shown to help in weight loss. (Novo Nordisk recently received approval to market its GLP-1 drug specifically for weight loss under the brand Saxenda.) Brand names for GLP-1 agonists available in the US market include Byetta and Bydureon (exenatide), Victoza (liraglutide), and Tanzeum (albiglutide). For more information about GLP-1 agonists, see Long-Acting Glucagon-Like Peptide 1 Receptor Agonists; A review of their efficacy and tolerability (Diabetes Care, 2011).
- SGLT-2 Inhibitors, taken by pill, which cause the kidney to release glucose into the urine, lowing blood glucose and potentially helping with weight loss, though weight loss is not a primary indication. Brand names for SGLT-2 inhibitors available in the US market include Invokana (canagliflozin), Jardiance (empagliflozin), and Farxiga (dapagliflozin).
Adults with type 1 who struggle to achieve their glucose targets may wish to discuss these new drugs with their diabetes care team. While off-label for type 1 diabetes, these medications have been shown to make a difference.
For More Information
- Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition. Free full text available in HTML format.
- Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Free full text available in HTML and PDF formats.
- Liraglutide as additional treatment for type 1 diabetes. Free full text available in HTML and PDF formats.
- Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial.
- Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
|Return to the Top of This Page|
Last Updated: Wednesday December 31, 2014 21:07:41
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.